Cone-Rod Dystrophy (CRD)
A group of inherited retinal diseases that affect the cone and rod photoreceptor cells of the retina, causing progressive vision loss.
Understanding Cone Dystrophy (COD) and Cone-Rod Dystrophy (CORD)
Cone dystrophy (COD) and cone-rod dystrophy (CORD) are rare inherited eye conditions that affect the retina, the light-sensitive tissue at the back of the eye. Both conditions begin with damage to cone photoreceptors, which are responsible for sharp central vision, color vision, and seeing in bright light.
In cone dystrophy (COD), cone cells are primarily affected. In cone-rod dystrophy (CORD), the disease starts in cone cells but later affects rod cells as well, leading to additional problems with night vision and peripheral (side) vision.
Because cone cells are concentrated in the macula, the center of the retina, central vision can be affected early and significantly. Symptoms often begin during childhood, adolescence, or early adulthood and gradually worsen over time.
1 in 30,000–40,000
Estimated prevalence
30+
Identified genes
30%-60%
Of autosomal recessive cases associated with ABCA4
How Cone-Rod Dystrophy can affect vision
Blurred & reduced central vision
Damage to cone cells can make it difficult to see fine details, read, recognise faces, or perform tasks requiring sharp vision.
Reduced color vision or color discrimination
Because cone cells are responsible for colour perception, people with CRD may experience changes in their ability to distinguish colours.
Light sensitivity (Photophobia)
Many people experience discomfort in bright environments or increased sensitivity to glare.
Difficulty seeing in bright environments
Some individuals find it harder to see clearly in daylight or brightly lit environments.
Difficulty seeing in low light
Progressive rod involvement may lead to night blindness or difficulty adapting to darkness.
Loss of peripheral vision
As rod cells become affected, side vision may gradually decrease.
In CORD, where rod cells become affected, patients may also experience:
- Night blindness
- Difficulty adapting to darkness
- Reduced peripheral (side) vision
Identifying Cone-Rod Dystrophy
Eye examination
An eye care professional (an optometrist or an ophthalmologist) will examine the retina and assess changes associated with the condition.
Visual field testing
Visual field testing measures how much of your surroundings you can see while looking straight ahead and helps track changes in your vision over time.
Retinal imaging
Special scans (Optical coherence tomography) and photographs ( fundus photography) of the retina help doctors see changes at the back of the eye.
Electroretinography (ERG)
This test measures how well the cells in your retina respond to light and helps assess retinal function.
Genetic testing
The results can help explain how the condition is inherited, guide care, and determine whether you may be eligible for research studies or clinical trials.
Supporting vision and independence
Low vision aids and magnifiers
Magnifying glasses, electronic magnifiers and other low vision aids can help make reading, recognising objects and everyday tasks easier.
Screen readers and accessibility technology
Screen-reading software, text-to-speech tools, screen magnification and adjustable display settings can support access to digital content and technology.
Vision rehabilitation programmes
Specialist rehabilitation services can help people develop practical strategies to manage vision loss, maintain independence and navigate everyday activities.
Educational and workplace support
Reasonable accommodations, accessible learning materials, assistive technology and workplace adjustments can help individuals participate in education and employment.
Genetic counselling
Genetic counselling can help individuals and families understand the inherited nature of cone dystrophy, potential inheritance patterns and available genetic testing options.
Mental health and emotional support
Counselling, peer support groups and mental health services can help individuals manage the emotional impact of progressive vision loss and connect with others with similar experiences.
Emerging treatments
Researchers are actively developing treatments aimed at slowing disease progression or preserving vision.
Gene Therapy
Several investigational therapies are designed to replace faulty genes, particularly ABCA4, one of the most common causes of COD/CORD.
RNA Editing
New technologies aim to repair or bypass disease-causing genetic errors at the RNA level.
Optogenetics
Experimental therapies, such as MCO-010, are designed to make surviving retinal cells responsive to light, potentially restoring some visual function.
Neuroprotective Treatments
Gene-agnostic therapies such as OCU410ST aim to reduce inflammation and protect retinal cells regardless of the underlying mutation.
Oral Therapies
Drugs including tinlarebant and gildeuretinol (ALK-001) are being studied to reduce the buildup of toxic by-products that contribute to retinal damage.
Many of these approaches are currently being evaluated in clinical trials.
Some Key Facts about CRD/CORD
2 Related Conditions
Cone Dystrophy (COD)
- Primarily affects cone photoreceptors
- Central vision affected first
- Peripheral and night vision often remain relatively preserved initially
Cone-Rod Dystrophy (CORD)
- Affects both cone and rod photoreceptors
- Starts with central vision problems
- Progresses to night vision and peripheral vision loss
30+ Genes Associated
Common genes linked to COD/CORD include:
- ABCA4
- GUCY2D
- RPGR
- KCNV2
Up to 80% Genetically Diagnosed
Genetic testing can identify the underlying cause in many patients, helping with diagnosis, family planning, and clinical trial eligibility.
Early Impact on Vision
- Low vision often develops in the second decade of life in COD.
- Vision loss may begin in the first decade of life in CORD.
- Around half of patients may reach legal blindness by their early 30s.
Future of Treatment
While cone dystrophy and cone-rod dystrophy remain rare and potentially blinding conditions, advances in genetic testing, retinal imaging, gene therapy, optogenetics, and RNA-based treatments are improving diagnosis and creating new treatment opportunities. Early diagnosis, low-vision support, and participation in clinical research are helping to improve outcomes for people living with these inherited retinal diseases.
Adapting to changing vision
Although COD and CORD can lead to significant vision loss, many people continue to live active and independent lives with the help of assistive tools and support services.
Helpful strategies include:
- Using magnifiers and low-vision devices
- Optimizing lighting and reducing glare
- Using screen-reading software and accessibility features
- Working with low-vision specialists
- Joining patient support groups and advocacy organizations
Advancing the future of CRD treatment
Gene therapy
Researchers are investigating gene replacement approaches to restore the function of genes affected in CRD.
Retinal cell therapies
Scientists are investigating whether damaged photoreceptor cells can be replaced or supported.
Retinal prostheses and vision restoration technologies
Retinal prostheses and vision restoration technologies use innovative devices and technologies to stimulate remaining retinal pathways and support vision.
Natural history studies and registries
Natural history studies and registries collect long-term data to better understand how this disease progresses and to guide future treatment development.
Clinical trials
Clinical trials are investigating potential treatments for different genetic forms of CRD.
Information and community connection
Take the Next Step
Cone-Rod Dystrophy highlights the importance of genetic research and patient-centred innovation in advancing the future of retinal health.
Through collaboration between patients, families, researchers, clinicians, and organisations worldwide, progress continues towards earlier diagnosis, improved support, and new treatment possibilities.
-
close